NeurologyLive® Friday 5 — October 20, 2023
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 20, 2023.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: Reviewing the Utilization of Serum Biomarker Tests for Diagnosing Multiple Sclerosis: William Kilgo, MD
The director of the neurology residency program and assistant professor of neurology at the University of South Alabama College of Medicine shared his insights from a year’s worth of using a serum biomarker test for the diagnosis of multiple sclerosis. [WATCH TIME: 5 minutes]
2: Enhancing Disability Monitoring in Multiple Sclerosis Using Digital Tools: Mikael Cohen, MD
The senior neurologist at the University Hospital Center of Nice in France talked about a digital tool developed to monitor disability more accurately in patients with multiple, especially during the early stages of the disease. [WATCH TIME: 5 minutes]
3: NeuroVoices: Diana Gallagher, MD, on New Phase 2 FUSION Study of BTK Inhibitor BIIB091
The head of Biogen’s MS and Immunology Department Unit provided an overview of FUSION, a currently recruiting study assessing the efficacy and safety of BIIB091 as a monotherapy and in combination with diroximel fumarate.
4: The Unresolved Bottleneck of Accessing Care for Mental Health in MS: Bernd C. Kieseier, MD
The global program head of the development unit for neuroscience at Novartis talked about the evolving landscape of mental health care for multiple sclerosis including the accessibility barrier that remains for patients in many regions. [WATCH TIME: 4 minutes]
5: Unpacking the Controversy of Hormone Therapy in Multiple Sclerosis: Melinda Magyari, MD
The neurologist in the Danish Multiple Sclerosis Center at Copenhagen University Hospital discussed the debate surrounding the use of hormone therapy in multiple sclerosis treatment, highlighting the need for more clinical evidence to support its use. [WATCH TIME: 5 minutes]
